A retrospective study of safety of ustekinumab and vedolizumab in an elderly real-life inflammatory bowel disease population
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- 07 Dec 2021 New trial record